All In MedTech

Device Trial Radar · NCT05026658

Prospective, Randomized, Controlled Agreement and Reproducibility Clinical Study

A Prospective, Randomized, Controlled Clinical Study to Evaluate the Agreement and Reproducibility of Visibly Digital Acuity Product

Last checked: Nov 19, 2026Latest source record: Nov 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 358 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

358

Actual

Start

Jul 22, 2021

Primary completion

Oct 4, 2021

Study completion Oct 4, 2021

Sponsor

Lead sponsor
VisiblyNot on our public-company list
Sponsor type
Industry
First posted
Aug 30, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated device
Yes
Who can join
All sexes, from 22 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Visual acuity is the relative ability of the eye to resolve detail that is usually expressed as the reciprocal of the minimum angular separation in minutes of two lines just resolvable as separate and that forms in the average human eye an angle of one minute. Visibly Inc. has developed a method for determining a patient's visual acuity electronically via a web-based software system that can be self-administered wherever convenient. This method provides an efficient alternative for people to have immediate access to visual acuity measurements.

Conditions

  • Digital Acuity Product

Interventions

  • Visibly Digital Acuity ProductDevice

    The order of testing (two VDAP home environments and ETDRS) will be randomly assigned for each subject as one of four sequences: 1. V1, E, V2 2. E, V1, V2 3. V2, E, V1 4. E, V2, V1 Where E denotes the ETDRS assessment, V1 denotes the VDAP assessment in home environment 1, and V2 denotes the VDAP assessment in home environment 2. The randomization will be blocked in groups of 4 subjects to ensure balance for the VA testing sequences.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. EffectivenessTime frame: Up to 3 hours
  2. ReproducibilityTime frame: Up to 3 hours

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Andover Eye Associates

    Andover, Massachusetts

  • Core, Inc

    Shelby, North Carolina

  • Total Eye Care

    Memphis, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.